clinical trial · NCT04740814
A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
UCB Biopharma SRL·phase1·completed·n = 33
Rheumatoid ArthritisCertolizumab pegol
brief summary
The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.
started
Feb 11, 2021
primary completion
Jan 24, 2022
completion
Jun 27, 2022
last updated
Feb 12, 2024
official title
A Multi-Center, Open-Label Study to Evaluate the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Using an Electrochemiluminescent Immuno-Assay
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol